These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2115448)

  • 1. A thirty year journey in the polyol pathway.
    Kinoshita JH
    Exp Eye Res; 1990 Jun; 50(6):567-73. PubMed ID: 2115448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of polyol pathways in formation of diabetic cataracts].
    Sabasiński K; Andrzejewska-Buczko J
    Klin Oczna; 1997; 99(6):401-4. PubMed ID: 9685789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase in diabetic complications of the eye.
    Kinoshita JH; Fukushi S; Kador P; Merola LO
    Metabolism; 1979 Apr; 28(4 Suppl 1):462-9. PubMed ID: 45423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF; Inoue J; Secchi EF; Lizak MJ; Rodriguez L; Mori K; Greentree W; Blessing K; Lackner PA; Sato S
    Exp Eye Res; 1998 Aug; 67(2):203-8. PubMed ID: 9733586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rat kidney aldose reductase and aldehyde reductase and polyol production in rat kidney.
    Sato S
    Am J Physiol; 1992 Nov; 263(5 Pt 2):F799-805. PubMed ID: 1443170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase in diabetic microvascular complications.
    Chung SS; Chung SK
    Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
    Bosquet F; Grimaldi A
    Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens.
    Lee AY; Chung SK; Chung SS
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2780-4. PubMed ID: 7708723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyol pathway-dependent osmotic and oxidative stresses in aldose reductase-mediated apoptosis in human lens epithelial cells: role of AOP2.
    Kubo E; Urakami T; Fatma N; Akagi Y; Singh DP
    Biochem Biophys Res Commun; 2004 Feb; 314(4):1050-6. PubMed ID: 14751239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of polyol pathway to oxidative stress in diabetic cataract.
    Lee AY; Chung SS
    FASEB J; 1999 Jan; 13(1):23-30. PubMed ID: 9872926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and morphological changes during development of sugar cataract in Otsuka Long-Evans Tokushima fatty (OLETF) rat.
    Kubo E; Maekawa K; Tanimoto T; Fujisawa S; Akagi Y
    Exp Eye Res; 2001 Sep; 73(3):375-81. PubMed ID: 11520112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications].
    Nishimura-Yabe C
    Nihon Yakurigaku Zasshi; 1998 Mar; 111(3):137-45. PubMed ID: 9583077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of aldose reductase in cataracts in human diabetes.
    Varma SD; Schocket SS; Richards RD
    Invest Ophthalmol Vis Sci; 1979 Mar; 18(3):237-41. PubMed ID: 106020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.
    Sato S; Mori K; Wyman M; Kador PF
    Exp Eye Res; 1998 Feb; 66(2):217-22. PubMed ID: 9533847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.
    Grewal AS; Thapa K; Kanojia N; Sharma N; Singh S
    Curr Drug Metab; 2020; 21(14):1091-1116. PubMed ID: 33069193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.